Single Dose Amikacin for Uncomplicated Cystitis in the ED: A Feasibility Study

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age14-110
SponsorAntonios Likourezos

About this trial

The purpose of this study is to determine if a single dose of amikacin (a type of antibiotic) can be used to effectively treat emergency department patients with uncomplicated cystitis (inflammation of the bladder). Participating in this study will allow the patient to treat their urinary tract infection (UTI) with a single intramuscular (IM (into the arm)) or intravenous (IV (into the vein)) shot of amikacin, rather than having to go to the pharmacy to pick up a prescription for antibiotics, and then take antibiotics for 3-7 days. A single dose of amikacin has been demonstrated to be safe, effective and well tolerated in other studies, but some patients may decline to participate because they do not wish to have an IV or IM shot, or because they don't want to speak on the phone with a research assistant three times over the next 30 days.

Eligibility criteria

Qualifiers

female emergency medicine patients

≥14 years of age

uncomplicated urinary tract infection

a primary urinary complaint and nitrite-positive urine.

Disqualifiers

pregnancy

abnormal genitourinary tract

recent urinary tract instrumentation

immunosuppression

Trial design

Treatments tested in this trial

  • Amikacin

Treatment groups

75 Participants
are divided into 1 treatment group

Sponsors and collaborators

Antonios Likourezos

Lead sponsor

Maimonides Medical Center

Sponsor institution